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antonia.velazquez@uab.catAbstractThyroid hormone receptors, THRA and THRB, together with the TSH receptor, TSHR, are key
regulators of thyroid function. Alterations in the genes of these receptors (THRA, THRB and
TSHR) have been related to thyroid diseases, including thyroid cancer. Moreover, there is
evidence suggesting that predisposition to differentiated thyroid cancer (DTC) is related to
common genetic variants with low penetrance that interact with each other and with
environmental factors. In this study, we investigated the association of single nucleotide
polymorphisms (SNPs) in the THRA (one SNP), THRB (three SNPs) and TSHR (two SNPs) genes
with DTC risk. A case–control association study was conducted with 398 patients with
sporadic DTC and 479 healthy controls from a Spanish population. Among the
polymorphisms studied, only THRA-rs939348 was found to be associated with an increased
risk of DTC (recessive model, odds ratioZ1.80, 95% confidence intervalZ1.03–3.14,
PZ0.037). Gene–gene interaction analysis using the genotype data of this study together
with our previous genotype data on TG and TRHR indicated a combined effect of
the pairwises: THRB-TG (PinteractionZ0.014, THRB-rs3752874 with TG-rs2076740;
PinteractionZ0.099, THRB-rs844107 with TG-rs2076740) and THRB-TRHR (PinteractionZ0.0024,
THRB-rs3752874 with TRHR-rs4129682) for DTC risk in a Spanish population. Our results
confirm that THRA is a risk factor for DTC, and we show for the first time the combined effect
of THRB and TG or TRHR on DTC susceptibility, supporting the importance of gene–gene
interaction in thyroid cancer risk.Key Words
" thyroid-function genes
" association
" thyroid cancer risk
" cancer susceptibilityific
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proEndocrine Connections
(2012) 1, 68–77IntroductionThyroid cancer is of special concern in endocrinology
practice, accounting for more than 90% of all endocrine
cancers. Moreover, its incidence is increasing in developed
countries (1, 2). Differentiated thyroid carcinoma (DTC)represents more than 90% of thyroid neoplasms, and it
comprises papillary (PTC) and follicular (FTC) histological
subtypes (3). The genetic predisposition to thyroid cancer
is estimated to be higher than in other common cancersa Ltd. This is an Open Access article
mmons Attribution License, which
duction in any medium, provided the
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Research S Pastor et al. Thyroid function genes 2–10 1 :69and, together with environmental factors, is considered
the main component in the aetiology of thyroid cancer
(4, 5, 6, 7).
Association studies have identified several genetic
variants related to thyroid cancer risk, including 8q24,
1p12, 9q22.23, 14p13.3 and 5q33 (8, 9, 10, 11, 12).
Polymorphic variations in the FOXE1 and NKX2-1 genes,
both involved in thyroid function and development of
the thyroid gland, have also been reported to be associated
with the risk of thyroid cancer (10, 13, 14). Furthermore,
common genetic variants associated with low levels of
TSH and increased thyroid cancer risk suggest the role of
thyroid-related hormones in thyroid cancer susceptibility
(15), including thyroid hormone receptors (TRs) and TSH
receptor (TSHR), which are key proteins in the regulation
of the thyroid function. Although mutations in the TR
genes, THRA and THRB, are not common in thyroid
tumours (16, 17, 18), a decreased expression of these genes
has been found in thyroid cancer (19).
These observations together with a study using mouse
models with deleted Thra and Thrb genes support the
tumour suppressor functions of the TR genes (20). Three
studies have reported the association of genetic variants
in the THRA gene with thyroid cancer risk, but the
conclusions are limited by the small size of the popu-
lations studied (21, 22, 23). In the case of THRB, there is
no reported data about THRB genetic variants related to
the thyroid cancer risk. The implication of TSHR in thyroid
cancer is unclear (24, 25). While epigenetic silencing of
TSHR in thyroid carcinomas has been reported (26),
two other studies have shown a lack of association of
TSHR polymorphisms with thyroid cancer risk (27, 28).
On the contrary, TSHR is associated with other thyroid
diseases (29).Table 1 General characteristics of the studied population: contro
Control Case
Total 479 398
Male, n (%) 196 (41) 89 (22)
Female, n (%) 283 (59) 309 (78)
Age: meanGS.D. 45.9G17.3 46.9G15.4
Male 49.9G18.1 47.5G14.3
Female 43.2G16.1 46.8G15.8a
Mean age at diagnostic 41.7G15.1
PTC, papillary thyroid cancer; FTC, follicular thyroid cancer.
aT-test, P!0.05, between control and cases.
bT-test, P!0.05, between PTC and FTC.
http://www.endocrineconnections.org
DOI: 10.1530/EC-12-0017Given the limited information concerning the impli-
cation of genes involved in the thyroid function on
thyroid cancer risk, in this study, we have analysed the risk
association between common genetic variants in the
THRA, THRB and TSHR genes and DTC in a large Spanish
population. In addition, we have examined the combined
effect of the variants of these three genes and the TG and
TRHR genes on DTC susceptibility, using data from our
previous association studies (12).Materials and methods
Subjects
The study was carried out on a Spanish population with
a total of 877 unrelated subjects who were recruited during
a 5-year period (2004–2008). A group of 398 newly
diagnosed patients with DTC (309 females and 89 males)
with a mean ageGS.D. of 46.99G15.45 years was recruited
at Vall d’Hebron Hospital (Barcelona) and at Josep Trueta
Hospital (Girona). Thyroid cancer patients were classified
as papillary cancer (85%) or follicular cancer (15%). The
control group consisted of 479 healthy cancer-free
volunteers (283 females and 196 males) with a mean age
GS.D. of 45.99G17.26 years. All subjects were Caucasians
with Spanish ancestry and from the same geographic area
(Table 1).
Individual information was obtained by personal
interview, and clinical information of patients was
obtained from medical history. All participants in the
study gave written informed consent. The study was
approved by the ethics committees of all the institutions
involved.l and thyroid cancer groups.
s PTC FTC
339 59
75 (22) 14 (24)
264 (78) 45 (76)
46.3G15.1 50.7G17.1
46.7G14.0 51.9G15.7
46.2G15.4a 50.3G17.6a
40.9G14.6 46.2G16.8b
 2012 The Authors. Published by BioScientifica Ltd. This is an Open Access article
distributed under the terms of the Creative Commons Attribution License, which
permits unrestricted use, distribution, and reproduction in any medium, provided the
original author and source are credited.
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Research S Pastor et al. Thyroid function genes 3–10 1 :70Single nucleotide polymorphisms selection
THRA and THRB and TSHR receptors are critical for the
function of the thyroid gland via the pituitary–thyroid
axis (see Fig. 1). The selection of the single nucleotide
polymorphisms (SNPs) in these genes was based on the
information available in the literature and public data-
bases. The selection criteria were based on the minor allele
frequencyO0.1. A total of six tagSNPs at the THRA, THRB
and TSHR genes were selected for the study. More detailed
information of the studied SNPs is described in Table 2.DNA preparation and genotyping
DNA for both cases and controls was isolated preferentially
from peripheral blood mononuclear cells using the
standard phenol–chloroform method. For some controls,
DNA was obtained from saliva samples using the Oragene
DNA Self-Collection kit (DNA Genotek, Ottawa, Ontario,
Canada). DNA concentration and purity were measured
with a Nanodrop 1000 spectrophotometer (ThermoFigure 1
Scheme of the thyroid hormone production and regulation on the
hypothalamus–pituitary–thyroid axis.
http://www.endocrineconnections.org
DOI: 10.1530/EC-12-0017Scientific, Waltham, MA, USA). The samples were stored
atK20 8C until use.
All genotype analyses were performed at the Spanish
National Genotyping Centre (CeGen, Santiago de
Compostela, Spain) using MassArray Sequenom
technology (Genome, San Diego, CA, USA) with the
iPLEX strategy. SNP genotyping was performed using a
custom-made SNP panel. Genotyping reliability was
guaranteed through double genotyping by replicating
10% of samples at random in multiple 96-well plates. In
addition, two HapMap reference trios were incorporated
in the plates, and the genotype concordance and correct
Mendelian inheritance were verified.Statistical analysis
The SNPStats software (30), SPSS (PASW statistics v17.0)
and GraphPad software were used to perform all the
statistical analyses. Comparison of the sex proportion
between cases and control groups and the Hardy–
Weinberg equilibrium test of the genotype distribution 2012 The Authors. Published by BioScientifica Ltd. This is an Open Access article
distributed under the terms of the Creative Commons Attribution License, which
permits unrestricted use, distribution, and reproduction in any medium, provided the
original author and source are credited.
Table 2 Information of the studied SNPs and allele frequencies between cases and controls in a Spanish population.
Chromosome MAF
Gene SNP ID Number Positiona
Nucleotide
change
Gene
polymorphism
Control
nZ479 Cases nZ398 P valueb
THRA rs939348 17 35485379 C/T Intron 2 0.25 0.28 0.25
THRB rs3752874 3 24159999 C/T Phe245Phe 0.16 0.14 0.23
rs826377 3 24143435 T/C Intron 9 0.18 0.19 0.91
rs844107 3 24138025 A/G 3 0-UTR 0.38 0.37 0.60
TSHR rs11845164 14 80601507 C/T Intron 2 0.14 0.15 0.60
rs8019570 14 80619348 A/G Intron 3 0.14 0.15 0.58
n, number of subjects; MAF, minor allele frequency; SNP, single nucleotide polymorphisms.
aPosition according to NCBI reference sequence.
bTwo-sided c2 test for distribution of allele frequencies.
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Research S Pastor et al. Thyroid function genes 4–10 1 :71in the control population were examined using the c2 test
with a 5% level of significance. Mean ages of cases and
controls were compared by the T-test. The thyroid cancer
risk was assessed using unconditional logistic regression
analyses, adjusted for gender and age, to determine the
odds ratios (OR) and 95% confidence intervals (CI). Tests
for interaction were performed including the cross
product of the respective variant alleles. The Haploview
software (31) was used to examine the linkage disequili-
brium (LD) between adjacent SNPs and to define haplo-
type block structures. The entire tests were two sided and
P!0.05 was considered statistically significant.Results
The characteristics of the population used in this study are
summarized in Table 1. The gender distribution in patients
and controls was different (78 and 59% females respect-
ively, P!0.0001). Further analysis of the genotype distri-
bution within gender in the control group has showed no
statistically significant differences between males and
females (data not shown). Thus, in our population, the
different sex proportion in patients and control groups did
not influence the successive association analysis.Association of individual SNPs with risk of DTC
The allele frequencies for the six SNPs studied are shown in
Table 2. No significant differences in the allele frequency
were observed between cases and controls for any of the
SNPs studied, although for the THRA-rs939348 a slight
difference in cases with respect to controls was observed
(0.28 and 0.25 respectively). The Hardy–Weinberg analysis
of the control group showed that the genotypehttp://www.endocrineconnections.org
DOI: 10.1530/EC-12-0017distribution was in equilibrium for the six genotyped
polymorphisms (PZ0.07–0.92).
Table 3 shows the genotype distribution of the SNPs
studied and the association analysis with DTC, in the total
patient group, and in PTC and FTC subgroups. No
significant differences in the ORs were observed between
controls and patients for either of the three SNPs
genotyped in THRB or the two genotyped SNPs in TSHR.
In the case of the THRA gene, for the rs939348
polymorphism, the logistic regression analysis (co-
dominantmodel) showed an increase in the risk of thyroid
cancer. The ORs of the homozygous variant (TT) for this
SNP were ORZ1.71 (95% CIZ0.97–3.03, PZ0.082) for the
total of cases, ORZ1.59 (95% CIZ0.87–2.91, PZ0.19) for
PTC andORZ2.51 (95%CIZ1.01–6.24, PZ0.098) for FTC.
These risk estimates suggest that the variant allele (T) could
act as a recessive risk factor for DTC. Thus, we next
evaluated the risk assessment for this polymorphism
according to the recessive model. As shown in Table 3, a
statically significant associationof thehomozygousvariant
was observed with DTC (ORZ1.80, 95% CIZ1.03–3.14,
PZ0.037); moreover, the association of the homozygous
variantwasalso significant for theFTCsubgroup (ORZ2.70,
95% CIZ1.12–6.49, PZ0.037) and marginally significant
for PTC (ORZ1.66, 95%CIZ0.92–3.01, PZ0.092). The lack
of significant association for the papillary type is most
likely due to the low number of homozygous individuals
for the variant allele in our population.Analysis of gene–gene interactions and risk of DTC
Given the functional relationship between THRA, THRB,
TSHR and TRHR, we decided to evaluate the combined
effect of common genetic variants of these genes on 2012 The Authors. Published by BioScientifica Ltd. This is an Open Access article
distributed under the terms of the Creative Commons Attribution License, which
permits unrestricted use, distribution, and reproduction in any medium, provided the
original author and source are credited.
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Research S Pastor et al. Thyroid function genes 6–10 1 :73thyroid cancer susceptibility. We performed gene–gene
interaction analysis on the pairwise SNPs of either THRA or
THRB with TSHR, TG and TRHR. For the interaction
analysis, we used the genotype results of this study
together with the TG and TRHR genotype data of our
previous association study (12). In both the studies, the
same Spanish population was genotyped. No significant
interaction for risk of DTC was observed in the pairwise
SNPs that included the THRA-rs939348 polymorphism
(data not shown), although, as indicated before, this
polymorphism showed an individual association with
thyroid cancer in the study population (see Table 3).
Because two of the three THRB SNPs, rs3752874 and
rs826377, are in LD (D 0Z0.98, r2Z0.36), we explored theTable 4 Risk of DTC associated with the combination of rs3
polymorphisms.
THRB rs37
CC
Controls/cases OR (95% CI) C
TG
rs2076740
CC 128/106 1.00 4
CT 147/123 0.94 (0.65–1.34) 6
TT 40/44 1.30 (0.78–2.16) 3
TRHR
rs4129682
CC 85/83 1.00 4
CT 163/154 0.93 (0.63–1.37) 7
TT 80/50 0.57 (0.36–0.92) 2
THRB rs84
AA
Controls/cases OR (95% CI) C
TG
rs2076740
CC 66/55 1.00 9
CT 81/75 0.97 (0.59–1.59) 1
TT 18/23 1.58 (0.76–3.29) 5
TRHR
rs4129682
CC 47/51 1.00 7
CT 87/81 0.84 (0.50–1.40) 1
TT 42/26 0.52 (0.27–1.00) 6
OR, odds ratio adjusted for age and gender; CI, confidence interval.
http://www.endocrineconnections.org
DOI: 10.1530/EC-12-0017interaction of THRB-rs3752874 and the third THRB SNP,
rs844107, with TSHR, TG and TRHR genetic variants. In
the interaction analysis of two genes, the stratification of
the population leads to a reduction of the number of
individuals, decreasing the statistical power of the
analysis. Therefore, to eliminate such effect for each
THRB polymorphism (rs3752874 or rs844107), we com-
bined the heterozygous and the homozygous variant
individuals as the variant carriers.
Certain combinations between the THRB polymorph-
isms (rs3752874 or rs844107) and polymorphisms in TG
(rs2076740) or TRHR (rs4129682) genes were significantly
associated with the risk of DTC. However, neither of
these markers, individually, contribute to the DTC risk752874 and rs844107 of THRB and different TG and TRHR
52874
CTCTT
ontrols/cases OR (95% CI) P for interaction
0.014
4/46 1.17 (0.71–1.93)
5/43 0.77 (0.48–1.23)
0/9 0.35 (0.16–0.79)
0.0024
4/17 0.41 (0.21–0.76)
7/63 0.76 (0.48–1.20)
5/28 1.14 (0.61–2.15)
4107
AGCGG
ontrols/cases OR (95% CI) P for interaction
0.099
5/95 1.11 (0.69–1.78)
27/86 0.76 (0.48–1.21)
1/30 0.65 (0.36–1.17)
0.11
6/46 0.58 (0.33–1.01)
46/132 0.79 (0.49–1.26)
0/52 0.74 (0.42–1.29)
 2012 The Authors. Published by BioScientifica Ltd. This is an Open Access article
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between the THRB polymorphisms and TSHR-rs8019570,
TSHR-rs11845164, TG-rs180223, TG-rs853326 or TRHR-
rs7823804 showed no statistically significant association
with DTC risk (data not shown).
An interaction effect between genetic variants of THRB
and TG was found for thyroid cancer risk. Table 4
illustrates that THRB-rs3752874 (exon 7) showed a
significant interaction with TG-rs2076740 (PinteractionZ
0.014). The variant allele carriers for THRB-rs3752874
(CTCTT) together with the homozygous variant for
TG-rs2076740 manifested a 0.035-fold decrease in DTC
risk (95% CIZ0.16–0.79). A combination effect with
borderline significance (PinteractionZ0.099) was also
observed between THRB-rs844107 and TG-rs2076740.
The interaction between THRB and TRHR showed that
the THRB-rs3752874 (exon 7) polymorphism together
with TRHR-rs4129682 also had a protective effect for DTC
risk (PinteractionZ0.0024) (see Table 4). The highest
protective interaction was found between the THRB-
rs3752874 variant allele carriers and the TRHR-rs4129682
common allele homozygous (CC) that showed a 0.41-fold
decrease in DTC risk (95% CIZ0.21–0.76).Discussion
TRs together with the TSHR have crucial roles in the
pituitary–thyroid axis (see Fig. 1). The TSHR gene is
expressed in the thyroid follicular cells. The THRA and
THRB genes are not only ubiquitous transcription factors
but also key regulators of the thyroid function (32, 33).
Therefore, we postulated that genetic variants in THRA,
THRB and TSHR genes individually or in combination
with genetic variants in other thyroid function/regulator
genes (i.e. TG and TRHR) could be important in DTC
development. In this study, we provide evidence for the
association of THRA with DTC. In addition, we show that
an interaction exists between THRB and TSHR, TG or TRHR
that modifies the risk of developing DTC.
In the population studied, the THRA-rs939348 in the
5 0-noncoding region (intron 2) acted as a possible marker
for thyroid cancer susceptibility. According to the
co-dominant model, the homozygous variant showed an
increased risk of 1.71 (95% CIZ0.97–3.03; PZ0.082).
Although the statistical significance with the recessive
model was higher than with the co-dominant model
(PZ0.037; see Table 3), these results should be taken with
caution, as the number of the homozygous variant was
small in our population. Limited information is available
about genetic variants in THRA related to thyroid cancer.http://www.endocrineconnections.org
DOI: 10.1530/EC-12-0017In three earlier reports (21, 22, 23), the dinucleotide CA
repeated in the 3 0-noncoding region of THRAwas found to
be related to thyroid cancer. Two of these studies were
based in a case–control design (22, 23), but the con-
clusions were limited by the small size of the population
used. To some extent, our study, using a population of 877
individuals, confirms the above previous results. In this
study, we have examined a THRA polymorphism that
maps in the 5 0-UTR region, far away from the 3 0-UTR CA
repeat analysed in the previous studies, and our results
also indicated a role for the THRA gene in thyroid cancer
risk. Moreover, Onda et al. (21) have reported a correlation
of the 3 0-UTR CA repeat with THRA expression and thyroid
tumour aggressiveness. In contrast, no mutations in the
THRA gene have been described in thyroid tumours (18);
thus, the specific function of THRA in thyroid cancer
remains unclear. More recently, Zhu et al. (20) have shown
that a mouse model with deleted Thra and Thrb genes
developed FTC, suggesting a tumour suppressor function
of these genes in FTC.
Regarding the association of TSHR with thyroid
cancer, none of the two genetic variants of TSHR included
in our study (rs8019570 and rs11845164) modified the
susceptibility to DTC significantly, suggesting a lack of
influence of these polymorphisms on the development of
DTC. Indeed, the role of TSHR in thyroid cancer is not
clear; however, it is a major thyroid autoantigen, and
genetic variants in the TSHR gene have been described to
be associated with the risk of thyroid diseases (29). TSHR
mutations in DTC are unusual (29), but Xing et al. (26)
reported epigenetic silencing of TSHR in thyroid carci-
nomas. Two studies investigated TSHR polymorphisms
related to DTC, although no association was found
(27, 28). Altogether, our results confirm previous studies
supporting the lack of association between common
genetic variants of TSHR and DTC risk.
In this study, we found no significant association of
any of the three THRB SNPs with thyroid cancer when
analysed individually. Of these SNPs, rs3752874 and
rs826377 map in the ligand binding domain of the THRB
gene and they showed LD (D 0Z0.98, r2Z0.36) in our
population. The thirdTHRB SNPmaps in the 3 0-UTR region
of the gene. Genetic variants in the ligand binding domain
of the THRB gene have been reported to be associated with
serum TSH levels (32, 34), while the 3 0-UTR is involved in
the silencing of THRB by microRNAs in PTC (19). It is also
well established that THRB is important in thyroid cancer
development (33). Recently, the activity of THRB as a
tumour suppressor has been reported (20, 35), which is
correlated with a reduced THRB expression found in renal 2012 The Authors. Published by BioScientifica Ltd. This is an Open Access article
distributed under the terms of the Creative Commons Attribution License, which
permits unrestricted use, distribution, and reproduction in any medium, provided the
original author and source are credited.
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Research S Pastor et al. Thyroid function genes 8–10 1 :75cancer (36, 37, 38). In mice, certain Thrb mutations also
promoted the development of mammary tumours (39). As
a further contribution to all this evidence supporting the
role of THRB in cancer and particularly in thyroid cancer,
the present results represent, to our knowledge, the first
study investigating the relationship between THRB
variants and DTC risk and suggest that individual genetic
variants of THRB are not related to DTC risk. Nevertheless,
it is important to replicate these results in other popu-
lations and evaluate other genetic variants of THRB to
ascertain the implication of individual THRB polymorph-
isms in thyroid cancer susceptibility.
Furthermore, increasing evidence indicates that,
together with environmental factors, the interaction of
common genetic variants of low penetrance could be
major determinants for thyroid cancer susceptibility
(3, 40). Thus, we have explored the interaction of the
THRB gene and other thyroid function-related loci for
DTC risk. The reasoning behind these analyses was based
on the well-known relevance of THRB in DTC, together
with the fact that in this study neither of the individually
analysed THRB SNPs showed association with DTC. We
found a gene–gene interaction of THRB with TG or TRHR
for thyroid cancer susceptibility in the population studied.
The significant Pinteraction values found in this population
support the general notion that often no association is
detected for individual SNPs, but their effect is manifested
in combination with other SNPs. The THRB SNP that maps
in the 3 0-UTR region (rs844107) suggests a combined effect
with TG for thyroid cancer risk. As the THRB 3 0-UTR is
involved in the silencing of the THRB gene (19), we can
speculate that genetic variants in the gene encoding the
TG protein may produce a small variation in the function
of the protein that, in combination with a decrease in the
TR, would alter the susceptibility to thyroid cancer. The
TG polymorphism (exon 33, rs2076740), which has been
shown to interact with the 3 0-UTR THRB polymorphism
for DTC risk, maps in a cysteine-repetitive element in TG
that has been suggested to be involved in intracellular
hormone transport (41). This TG polymorphism is
associated with autoimmune thyroid disease (42, 43) but
showed no association with DTC (12). Therefore, another
possible explanation for the combined effect of TG and
THRB for thyroid cancer susceptibility could reside in the
alteration of the transport of the thyroid hormone
together with a decrease in the hormone receptor in the
follicular cells of the thyroid gland. On the other hand, the
genotyped THRB SNP that maps in the hormone binding
domain (rs3752874) has shown a combined effect with
either the TG-rs2076740 or the TRHR-rs4129682 forhttp://www.endocrineconnections.org
DOI: 10.1530/EC-12-0017thyroid cancer risk, and the interaction effect was more
than multiplicative (Pinteraction!0.05 and !0.01 respect-
ively). The combination of TG and THRB variants could
alter the hormone–receptor interaction for DTC risk.
Although no functional interaction is expected between
THRB and TRHR, we suggest that variations in the
function of these proteins could alter the regulation of
the thyroid function via the hypothalamic–pituitary–
thyroid axis with consequences in the risk for DTC.
In conclusion, this study confirms the association of
THRA with thyroid cancer in a Spanish population, and
it supports the lack of association of TSHR with thyroid
cancer as previously reported. Furthermore, this is the
first study reporting on the analysis of the association of
genetic variants in THRB with thyroid cancer. The
essential role of THRB in thyroid function has been
well documented. Here, our results suggest the import-
ance of genetic variants in THRB in combination with
polymorphisms in other genes of the thyroid function
(i.e. TG or TRHR) in determining thyroid cancer risk. In
line with other authors, our study indicates that the role
of gene–gene interaction could be crucial in cancer
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